CEO’s Insider Buying of KORU Shares Signals Confidence Amid Volatility

Insider Buying at KORU Signals Confidence Amid Volatility

A recent director‑dealing filing reveals that Chief Executive Officer Tharby Linda M has purchased 1,191 shares of KORU Medical Systems (ticker: KORU) at an average price of $3.92 on 15 May 2026. The transaction is part of a cluster of trades over the past month that increased the executive’s holdings from 619,431 to 620,622 shares. The acquisition price, slightly below the prevailing market price of $4.00, indicates that the CEO is taking advantage of a marginal dip in the stock’s valuation.

What the Buy Means for Investors

KORU’s share price has exhibited a mixed trend: a weekly gain of 3.9 % counterbalanced by a monthly decline of 6.1 %. The earnings outlook remains uncertain, with a negative price‑earnings ratio of –76.2 and a market capitalization of approximately $179 million. In such a context, sizeable insider purchases are often interpreted as a signal of management confidence in the company’s long‑term prospects, particularly when the trades are significant relative to the float. A sentiment score of +42 and a buzz level of 73 % on social‑media channels suggest that the market is reacting positively, though the intensity remains moderate.

Implications for KORU’s Future

The incremental ownership by the CEO, mirrored by similar buying activity from the COO and CFO, points to a strategic alignment among senior management. They appear to be positioning themselves to benefit from the projected growth in the subcutaneous infusion device market. Should KORU successfully expand its product pipeline or secure new payer contracts, the stock could recover from its 52‑week low of $2.63 to the high of $6.61 observed last year. Nevertheless, the company’s negative earnings multiple and the recent decline in its share price warrant caution; investors should closely monitor forthcoming quarterly results and any regulatory developments that could affect device approvals.

A Profile of CEO Tharby Linda M

Tharby’s transaction history demonstrates a disciplined, long‑term investment strategy. In March 2026, the CEO added 15,968 shares and sold 5,756 shares; in April 2025 she sold a large block of 23,587 shares at $2.20. The most recent purchase reflects a pattern of acquiring shares at or below market price, often following a dip. Her willingness to sell when prices rise and to buy when they fall indicates a focus on value rather than opportunistic trading. This approach, combined with the recent $3.92 purchase, aligns with a belief that KORU’s valuation will ultimately recover.

Bottom Line for Traders and Portfolio Managers

For those monitoring the health‑care equipment sector, KORU’s insider buying—particularly by the CEO—provides a subtle bullish signal amid a volatile environment. The stock’s modest liquidity and the company’s negative valuation metrics mean that a single trade may not move the market; however, cumulative insider activity could presage a shift in investor sentiment. Investors should weigh the CEO’s confidence against KORU’s financial fundamentals and upcoming product milestones before allocating capital.